DETAILED ACTION
Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
Priority
This application, filed 1 November, 2024, is a national stage application of PCT/US2023/066533, filed 3 May, 2023, which claims prior benefit of application PRO63/338,181, filed 4 May, 2022.
Information Disclosure Statement
Three information disclosure statements (IDS) submitted on 1 October, 2025; 5 March, 2026; and 21 May, 2026 are acknowledged and have been considered.
Status of the Application
Receipt is acknowledged of Applicant's claimed invention, filed 1 November, 2024, in the matter of Application N° 18/862,249. Said documents have been entered on the record.
Claims 4-8, 10-11, 13-14, 16-17, 19-20, 22-24, 28-29, 31-46, 49-50, 54-55, 67 are amended. No new matter was introduced.
Thus, Claims 1-68 represent all claims currently under consideration.
Claim Objections
Claim 37 is objected to because of the following informalities: the final conjunction “or” is listed prior to the second to last list item, rather than prior to the last item.
Appropriate correction is required.
Claim Rejections - 35 USC § 112
The following is a quotation of 35 U.S.C. 112(b):
(b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention.
The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph:
The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.
Claim 53 is rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention.
Claim 53 is incomplete in itself because it incorporates subject matter from the specification (“…compounds in Examples 2-5 and Tables 1-5”). Where possible, claims are to be complete in themselves. Incorporation by reference to a specific figure or table "is permitted only in exceptional circumstances where there is no practical way to define the invention in words and where it is more concise to incorporate by reference than duplicating a drawing or table into the claim. Incorporation by reference is a necessity doctrine, not for applicant’s convenience." Ex parte Fressola, 27 USPQ2d 1608, 1609 (Bd. Pat. App. & Inter. 1993). See MPEP §2173.05(s).
Claim Rejections - 35 USC § 102
In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status.
The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:
A person shall be entitled to a patent unless –
(a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention.
Claims 1-2, 4, 6, 8-9, 11-15, 17-18, 20-23, 25-26, 32-33, 36, 38-39, 42 and 44-45 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by PubChem CID: 75523012 (2014, cited in IDS and ISR).
PNG
media_image1.png
124
318
media_image1.png
Greyscale
PNG
media_image2.png
234
193
media_image2.png
Greyscale
4-Methyl-2-oxo-1-[[3-(2-phenylethyl)-1,2,4-oxadiazol-5-yl]methyl]pyridine-3-carbonitrile (PubChem CID: 75523012), shown top right, is fully encompassed by instant Formula I, shown bottom right, wherein Ring A is phenyl (as in instant Claim 24), L1 is -(CR5R6)n- wherein R5 and R6 are each independently H (as in instant Claims 8-9 and 11-14), n is 2 (as in instant Claim 6), L2 is -CR7R8- wherein R7 and R8 are each independently H (as in instant Claims 17-18 and 20-23), R1 is CN (as in instant Claims 32-33), R4 is H (as in instant Claims 44-45), Y is CR2 (as in instant Claim 2) wherein R2 is methyl (as in instant Claims 36 and 38), and Z is CR3 (as in instant Claim 4) wherein R3 is H (as in instant Claims 39 and 42).
Similarly, the compound is encompassed in the sub-formulae Ia and IIa, wherein R5a, R5b, R6a, and R6b are each independently H, and R11-R15 are each independently H (as in instant Claims 15 and 25-26).
As such, Claims 1-2, 4, 6, 8-9, 11-15, 17-18, 20-23, 25-26, 32-33, 36, 38-39, 42 and 44-45 are anticipated.
Claims 1-2, 5-6, 8-9, 11-15, 17-18, 20-23, 25-26, 32-33, 36, 38 and 44-45 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by PubChem CID: 126810833 (2017, cited in IDS and ISR).
PNG
media_image3.png
220
309
media_image3.png
Greyscale
PNG
media_image1.png
124
318
media_image1.png
Greyscale
5,6-Dimethyl-3-[[3-(2-phenylethyl)-1,2,4-oxadiazol-5-yl]methyl]pyrimidin-4-one (PubChem CID: 126810833), shown top right, is fully encompassed by instant Formula I, shown bottom right, wherein Ring A is phenyl (as in instant Claim 24), L1 is -(CR5R6)n- wherein R5 and R6 are each independently H (as in instant Claims 8-9 and 11-14), n is 2 (as in instant Claim 6), L2 is -CR7R8- wherein R7 and R8 are each independently H (as in instant Claims 17-18 and 20-23), R1 is methyl (as in instant Claims 32-33), R4 is H (as in instant Claims 44-45), Y is CR2 (as in instant Claim 2) wherein R2 is methyl (as in instant Claims 36 and 38), and Z is N (as in instant Claim 5).
Similarly, the compound is encompassed in the sub-formulae Ia and IIa, wherein R5a, R5b, R6a, and R6b are each independently H, and R11-R15 are each independently H (as in instant Claims 15 and 25-26).
As such, Claims 1-2, 5-6, 8-9, 11-15, 17-18, 20-23, 25-26, 32-33, 36, 38 and 44-45 are anticipated.
Double Patenting
The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).
A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b).
The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13.
The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer.
Claims 1-68 are provisionally rejected on the ground of nonstatutory double patenting as being unpatentable over Claims 1-59 of copending Application No. 18/835,428 in view of Subbaiah and Meanwell (J. Med. Chem. 2021, 64, 14046−14128).
Although the claims at issue are not identical, they are not patentably distinct from each other because the claimed compounds differ principally in the heteroatom placement within the pyridone/pyridazinone heterocyclic core, as shown below.
PNG
media_image4.png
123
311
media_image4.png
Greyscale
PNG
media_image5.png
165
352
media_image5.png
Greyscale
Instant Formula I
‘428 Formula I
However, Subbaiah and Meanwell expressly teach that variation in heteroatom placement within aromatic heterocycles constitutes a routine design choice used to explore predictable changes in electronic and steric properties (see Scheme 1, Figure 1, Table 2, etc.) Such positional isomerism does not alter the fundamental scaffold of the molecule and would have been an obvious modification to a person of ordinary skill in the art.
This is a provisional nonstatutory double patenting rejection because the patentably indistinct claims have not in fact been patented.
Communication
Any inquiry concerning this communication or earlier communications from the examiner should be directed to Donna M. Nestor whose telephone number is (703)756-5316. The examiner can normally be reached generally (w/flex): 5:30a-5p EST M-Th.
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Kortney Klinkel can be reached at 571-270-5239. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/D.M.N./ Examiner, Art Unit 1627
/SARAH PIHONAK/ Primary Examiner, Art Unit 1627